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Abstract  
Introduction: Radiosensitivity (RS) of South African women with breast cancer was 
investigated as it has been studied in European women, but to date this has not been studied in 
South African women. The micronucleus assay was used to determine the amount of DNA 
damage on lymphocytes of breast cancer patients.  
Materials and Methods: The first component to this study involved the collection of blood 
samples from breast cancer patients and healthy individuals. For the second component, blood 
samples from breast cancer patients were collected before and after the completion of 
radiotherapy (RT). A centromeric micronucleus assay using the Fluorescent in situ Hybridisation 
(FISH) pancentromeric probe was used to investigate the origin of the micronuclei (MN) and to 
distinguish between radiation-induced [centromere negative (CM-)] and spontaneous 
[centromere positive (CM+)] MN.  
Results: Micronucleus frequencies were slightly higher in breast cancer patients than those 
observed in lymphocytes of healthy donors. This was noted for the different radiation doses and 
indicated a trend towards an enhanced chromosomal radiosensitivity in this cancer population. 
Results were compared before and after radiotherapy. The micronucleus scores for the 0 Gy 
(sham irradiated samples) were significantly higher (p < 0.05) post radiotherapy. This is an 
expected result as ionising radiation causes more damage. However, blood samples from post-
therapy patients, were shown to have fewer MN after subsequent in vitro 2 Gy and 4 Gy 
irradiation respectively. When assessing the centromeric micronucleus assay results, a 
significantly (p < 0.05) higher number of CM- MN was observed than CM+ MN after RT, thereby 
indicating that ionising radiation causes more breaks in the chromosomes (clastogenic 
damage).  
Discussion and Conclusion: This study demonstrates that a group of South African breast 
cancer patients have slightly higher micronucleus frequencies compared to a population of 
healthy women, indicating a trend towards a higher sensitivity to radiation. 
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1. Introduction 
We compared chromosomal radiosensitivity (RS) in a cohort of South African 
breast cancer (BC) patients with healthy (cancer free) participants by assessing 
their lymphocytic responses to radiation by using the micronucleus assay. To 
date this has not been studied on the genetically diverse South African 
population before. The effects of various factors on micronucleus frequencies, 
such as the clinical and social data of BC patients, were also investigated. 
Amongst patients at Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH), it has been observed that South African BC patients react differently 
to radiation, compared to European BC patients. We therefore investigated the 
micronucleus frequencies of BC patients before and after their therapy.  
1.1 Radiobiology 
Radiobiology is the study of the sequence of events that occur in an organism 
following the absorption of energy from ionising radiation (IR). Radiation is 
described as any process in which energy emitted by one body travels through 
a medium or space, ultimately to be absorbed by another body (LaTorre Travis, 
2000). IR consists of subatomic particles or electromagnetic waves that have 
enough energy to detach electrons from atoms or molecules and ionise them 
and is frequently used in several medical and industrial applications (Joiner, 
van der Kogel & Steel, 2009). The important characteristic of IR is the localised 
release of large amounts of energy, which can break a strong chemical bond 
(Hall & Giaccia, 2012). Examples of IR are illustrated in figure 1.1. 
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Figure 1.1: Examples of IR are gamma rays, X-rays and cosmic rays (World Health 
Organisation). 
 
When ionising radiation interacts with a cell, it can either affect it directly or 
indirectly (Figure 1.2). Direct action occurs when an ionising particle interacts 
with, and is absorbed by, a biologic macromolecule (eg: DNA, RNA, proteins) 
within the cell. This absorption of energy results in ionisation and therefore 
damage of the biologic macromolecule. Indirect action occurs when the energy 
is absorbed through water, the medium surrounding the biologic 
macromolecules within the cell, resulting in the ionisation of water. This in turn 
induces chemical reactions such as ion pairs (H+, OH-) and free radicals (H·, 
OH·), which causes damage to the biologic macromolecules (LaTorre Travis, 
2000). 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
Figure 1.2: The two types of radiation damage on DNA: Direct action - direct damage to 
the biologic macromolecule; and Indirect action - damage to the biologic macromolecule 
through the ionisation of water (Hall & Giaccia, 2012). 
 
1.1.1 DNA damage and repair 
DNA is the most sensitive cellular target to radiation due to the fact that it 
carries genetic information and regulates all cellular activities, consequently 
having the most deleterious effect on the cell if it is damaged.  
 
DNA radiation damage can be divided into 4 categories (LaTorre Travis, 2000): 
1. Base damage: The loss or change of a base on the DNA strand. 
2. Single-stranded breaks (ssbs): Breaks in one of the DNA strands. 
3. Double-strand breaks (dsbs): Breaks in both backbones of the DNA 
strand. 
4. Crosslinking: The production of crosslinks between two complementary 
strands or different DNA molecules. 
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Dsbs are the most significant type as they cause information to be lost in both 
DNA strands and can result in misrepairs and chromosomal aberrations, which 
in turn can lead to mutations or cell death.  
 
1.1.1.1 DNA damage response 
The biological effects caused by ionising radiation which have been found to be 
phase dependant within the cell cycle, may result in DNA repair, programmed 
cell death or cell cycle arrest. IR causes dsbs which can result in the 
amplification, deletion or rearrangement of genes and therefore alter gene 
expression (Turnbill, Mirugaesu & Eeles, 2006). 
The DNA damage response (DDR) is governed by a number of signal 
transduction pathways that mainly consist of two components: one which 
involves the sensing and reporting of damage and another which involves the 
recruitment of molecules to fix the damage or induce apoptosis (Figure 1.3). 
After the sensor proteins are activated, the two main protein kinases, namely 
Ataxia Telangiectasa (AT) Mutated (ATM) and ATM+Rad3 related (ATR), are 
activated in the transducer pathway (Zhou & Elledge, 2002; Houtgraaf, 
Versmissen, & van der Giessen, 2006). Next ATM and ATR phosphorylate the 
mediator proteins (eg. P53 binding protein), which are specific to the type of 
damage as well as the point in the cell cycle. In the effector pathway, the 
serine/ threonine protein kinases Chk 1 and Chk 2 ultimately determine the fate 
of the damaged cell. This is either by cell repair, DNA transcription, cell cycle 
arrest or apoptosis.  
To initiate cell cycle arrest, Chk 1 and Chk 2 together with ATM and ATR act to 
reduce cyclin–dependent kinase (CDK). This inhibition slows down or arrests 
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cell–cycle progression at the G1-S, intra-S and G2-M cell cycle checkpoints 
(Jackson & Bartek, 2009). These events allow sufficient time for DNA damage 
to be assessed and fixed. If the damage is too complex, then DDR signalling 
triggers cell death by apoptosis or cellular senescence (Jackson & Bartek, 
2009). 
Cellular senescence is defined as the permanent arrest of a cell whereby it 
loses its ability to divide. When this process is elicited by cellular stresses, in 
this case ionising radiation, it is termed ‘premature’ senescence. This process 
is characterised by a flattened cytoplasm and increase in granularity or 
biochemically by an increase in senescence-associated β-galactosidase 
expression. These processes are all activated by various molecular pathways 
in the DDR system, which are not yet clearly understood (Wouters, 2009). 
 
The intrinsic apoptotic pathway, which is activated following the initiation of 
caspase 9, is triggered as a result of damage that occurs within the cell. The 
activation of caspase 9 precedes a cascade of proteins in or near the 
mitochondria that are activated following extensive DNA damage. Proteins 
involved include p53, BAX and cytochrome c (Wouters, 2009).  
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Figure 1.3: An outline of the DNA damage response signal-transduction pathway. This 
pathway consists of sensors, transducers, mediators and effectors. (Adapted from Zhou & 
Elledge, 2000). 
1.1.1.2 DNA repair mechanisms 
In the event of minor DNA damage, the DDR initiates cell repair. Various repair 
mechanism pathways are activated, which are in turn regulated by different 
genes. Damage caused by ionising radiation to the mammalian cell is repaired 
by 5 different repair mechanisms each depending on the type of damage done 
to the cell. These are base excision repair, nucleotide excision repair, mismatch 
repair, as well as homologous recombination and non-homologous end joining 
(Hoeijmakers, 2001) (Figure 1.4). Repair mechanisms help in the recovery 
process after radiotherapy (RT) and defective repair mechanisms can lead to 
radiosensitivity. 
DNA damage 
effectors 
Sensors      (eg: Rad) 
DNA repair transcription apoptosis Cell cycle arrest 
Transducers (eg: ATM, ATR) 
Mediators (eg: p53) 
(eg: Chk1, Chk2) 
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Figure 1.4: Different types of DNA repair mechanisms caused by ionising radiation and other 
agents (Hoeijmakers, 2001) 
 
Double strand breaks are the most common type of radiation-induced damage. 
The two DNA repair mechanisms involved in repairing double strand breaks are 
non-homologous end joining and homologous recombination.  
a) Homologous recombination 
This process involves the use of homologous DNA sequences to repair the 
damaged double stranded DNA during the late S & G2 phase of the cell cycle 
(Figure 1.5). This repair process is mostly error free (Wouters & Begg, 2009). 
Each strand is cut back with an exonuclease or helicase to leave a 3’ overhang 
from which the nucleotides will be added to, to form the new, repaired strand. 
 
A nucleoprotein filament is formed through the polymerisation of the Rad 51 
protein to the single-stranded DNA, which in turn searches for homologous 
DNA. In conjunction with Rad 51, other proteins such as Rad 52, Rad 54, Rad 
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55 / 57 and the single-strand DNA-binding proteins, replication protein A (RPA), 
are involved in the action of joining the homologous strands by forming a joint 
molecule. The DNA is then synthesised with DNA polymerase and ligase, the 
crossed strands fixed with resolvase and the result is two intact DNA strands 
(Kanaar, Hoeijmakers & van Gent, 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: An overview of the process of Homologous Recombination where DNA is repaired 
using homologous strands (Kanaar, Hoeijmakers & van Gent, 1998). 
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b) Non-homologous end joining 
With this process (illustrated in figure 1.6), which occurs during all stages of the 
cell cycle, two DNA strands are joined together without the need of a 
homologous template. This process is less accurate than HR and therefore the 
DNA strands will predominantly have more faults, which in turn can lead to 
mutations or apoptosis (Wouters & Begg, 2009). The KU heterodimer binds to 
the DNA ends and attracts DNA-PKCS. This causes the phosphorylation of the 
DNA-PKCS promoters, causing a structural change in the complex. The ends 
are processed by the RAD 50, MRE 11 and NBS 1 complex and lastly the DNA 
ligase IV XRCC4 complex re-joins the strands (Kanaar, Hoeijmakers & van 
Gent, 1998). 
 
 
 
 
 
 
 
 
 
Figure 1.6: The process of NHEJ involves the use of various proteins to bind the two 
fragmented DNA strands together (Kanaar, Hoeijmakers & van Gent, 1998). 
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1.1.2 Chromosomal aberrations 
Double and single strand breaks can lead to chromosomal aberrations. The 
process of how DNA breaks convert into visible chromosomal aberrations is still 
unclear. Different hypotheses are described in literature. The chromosomal 
aberrations can be divided in 2 groups: Chromosome and chromatid 
aberrations (Bryant, 1998; Bryant, Riches & Terry, 2010) (Figure 1.7), which 
include (LaTorre Travis, 2000): 
Acentric fragments – fragments of chromosomes that do not contain 
centromeres. 
Dicentrics – when the ends of two chromosomes that each contain a 
centromere join together. 
Translocations – the transfer of a segment of one chromosome to another 
chromosome.  
Deletions – the loss of a whole segment of a chromosome in one or both arms. 
Inversions – the reversal and re-annealing of the same fragment. In this 
process the fragment is reversed and re-annealed to the chromosome at the 
same breakage site. 
Rings – occur when the fragmented arms of the chromosome bind together, 
forming a ring. 
Chromatid exchange – An exchange of segments between the sister 
chromatids of a chromosome. 
Chromatid breaks – Breaks in one or both of the sister chromatids 
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Figure 1.7: The different types of chromosomal aberrations, which include acentric fragments, 
dicentrics, translocations and ring formations (Tubiana & Dutreix, 1990). 
 
1.1.3 Chromosomal radiosensitivity  
Enhanced chromosomal RS was initially described in patients with inherited 
cancer prone syndromes such as Ataxia telangiectasia, Fanconi’s anaemia and 
Nijmegen breakage syndrome (Sanford, et al., 1989). Later it became apparent 
that enhanced chromosomal RS is also present in significant proportions of 
patients with different cancers, such as head and neck, colorectal, prostate, 
cervix and lung cancer (Jones, et al., 1995; Parshad, et al., 1996; Riches, et al., 
2001). Several studies confirmed chromosomal RS to be present in breast 
cancer patients (Scott, et al., 1994, 1998, 1999; Baeyens, et al., 2002). 
However, none of these studies were done on an African population.  
Various studies have demonstrated that an increase in chromosomal 
radiosensitivity has been associated with an increase of late side effects of 
radiation therapy (West, et al., 2001; Hoeller, et al., 2003; De Ruyck, et al., 
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2005). It was noted that due to these late side effects resulting from RT, the 
dose level and therefore a chance of cure is limited (Borgmann, et al., 2008). 
For this reason, RS biodosimetry may be a good early predictor for patient 
specific late side effects. 
 
1.1.4 Mechanisms leading to radiosensitivity 
Several articles reviewed by Scott et al., (1999) suggest that defects in the 
repair mechanisms of radiation-induced DNA damage could lead to cancer 
predisposition and led to the idea that chromosomal aberration assays may be 
used as biomarkers of cancer risk.  
Various mechanisms have been found to contribute to RS. Some include 
defects in DNA repair pathways and cell cycle checkpoint control (Parshad, 
Sanford & Jones, 1983). Scott, et al. (1999) suggested that reasons for 
defective DNA repair pathways could be due to mutations of the downstream 
genes involved in the detection and/or regulation of DNA damage. Defective 
apoptotic pathways could also contribute to RS (Baeyens, 2005). 
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1.1.5 Cytogenetic testing 
Cytogenetic testing involves the study of cell structure, especially human 
chromosome function and structure. This is done by assessing chromosomal 
aberrations that may have been caused by genetic or environmental factors 
(Darroudi, 2008). It is usually carried out using blood or bone marrow samples. 
Cytogenetic tests are also used for radiation biodosimetry and radiosensitivity 
studies. The different cytogenetic assays used in radiobiology include the G2 
Assay, Micronucleus assay, Dicentrics assay, Comet assay and the Foci 
assay.  
a) The Cytokinesis-block micronucleus (CBMN) assay 
One of the assays to detect chromosomal aberrations is the Cytokinesis-block 
micronucleus assay. Micronuclei (MN) are small nuclear fragments that lag 
behind after nuclear division. MN can either occur spontaneously, through 
aneugenic events, whereby whole chromosomes lag behind during cell division 
or through clastogenic events, caused by agents such as ionising radiation, 
during which chromosomal breaks are created. These fragments or whole 
chromosomes are covered with a nuclear envelope at telophase, giving the 
micronucleus its structure (Fenech, 2000) (Figure 1.8).  
To stimulate the latent lymphocytes to divide, Phytohaemagglutinin (PHA) is 
added. As MN can be seen in dividing cells and are usually lost after division, 
the cytoplasmic inhibitor Cytochalasin B (Cyto B) is added. This inhibits cellular 
division, resulting in a binucleated (BN) cell (Fenech, 2000). Also, it allows to 
discriminate between cells which have undergone nuclear division and cells 
which have not. The number of MN following radiation is a marker of radiation-
14 
 
induced DNA damage. The micronucleus assay is a good biological dosimeter 
for radiation (Norppa & Falck, 2003).  
 
 
 
 
 
 
Figure 1.8: a) A BN cell containing a micronucleus. b) The process of micronucleus formation. 
(Baeyens, 2005).  
 
The advantages of using the micronucleus assay include its practicality, the 
allowance for taking the proportion of cell division into account as well as the 
ability to assess chromosome breakage or loss by examination of acentric 
fragments or whole chromosomes (Baeyens, et al., 2002; Varga, et al., 2004; 
Baeyens, 2005). The main disadvantage of the micronucleus assay is the high 
variability in spontaneous micronucleus frequency. 
Various factors have been discovered that could influence the number of MN 
produced. These include: age, sex (Thierens, et al., 2000), HIV status 
(Baeyens, et al., 2010), ethnicity (Amend, Hicks & Ambrosone, 2006), 
clastogenic medication, smoking and pre- or post-menopausal status (Dhillon & 
Dhillon, 1995; Ahmad, et al., 2000). 
a 
b 
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An automated microscopic system controlled by the Metafer 4 software 
program MetaSystems, which consists of a Zeis Axio Imager microscope with a 
camera attached, connected to a computer, can be used for automatic scoring 
of MN. The microscope has a motorised scanning stage able to hold 8 slides. 
The system scans the slide and takes pictures of each BN cell it finds as well 
as any micronucleus within the cytoplasmic boundary surrounding the nuclei, 
as specified on the system. These pictures are stored in a gallery on the 
computer for subsequent viewing (Schunck, et al., 2004).  
b) The Micronucleus-centromere assay 
The sensitivity of the micronucleus assay is restricted to a dose of 0.2 Gy. This 
is due to the high and variable spontaneous MN (Vral, Thierens & De Ridder, 
1997). These high variable numbers of MN are mostly due to lagging whole 
chromosomes (Thierens, Vral & De Ridder, 1996). Radiation-induced MN will 
mainly be a result of clastogenic damage, consisting of acentric fragments that 
are centromere negative (CM-), while spontaneous MN will be centromere 
positive (CM+) (Thierens & Vral, 2009).  
 
The combination of the Fluorescent In Situ Hybridisation (FISH) technique with 
a pancentromeric probe allows for the detection of the presence of a 
centromere in MN and allows discrimination between background MN and 
radiation-induced MN (Figure 1.9) Studies have shown spontaneous MN 
increase with age. This can be completely attributed to CM+ MN (aneugenic 
damage) reflecting an increased chromosome loss with age (Thierens, Vral & 
De Ridder, 1996).  
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Figure 1.9: Using the FISH pancentromeric probe, centromere positive (CM+) MN can be 
distinguished from centromere negative (CM-) MN by looking for the positive fluorescent 
signals (Iarmarcovai, Botta & Orsiére, 2006). 
The pancentromeric probe hybridises to all the centromeres of all the 
chromosomes in the main nuclei, as well as to any micronucleus containing 
centromeres (Figure 1.10).  
This specific probe is commercially available (known as STAR FISH, SR 
Biosystem ©). However, for research purposes, an in-house probe can be 
made using the nick-translation method, which is more cost effective.  
   
Figure 1.10: a) Binucleated cell with a centromere negative micronucleus;  
b) Binucleated cell with a centromere positive micronucleus with 2 signals. Both MN are 
indicated by an arrow (Vral, Fenech & Thierens, 2011). 
a) b) 
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1.2 Breast Cancer 
1.2.1 Background 
Breast cancer is the leading cancer in females and accounts for approximately 
18 % of all cancer cases in women worldwide (American Cancer Society, 
2011). In South Africa, 1 in 29 women are diagnosed with BC each year. The 
2000-2001 National Cancer Registry (NCR) Report shows that women have a 
lifetime risk of 1 in 8 of getting breast cancer (NCR, 2004). 
 
The breast is made up of roughly 18 lobules of glandular tissue, which in turn 
consists of alveoli. These lobules of glandular tissue are surrounded by fat 
tissue, giving breasts their shape (Figure 1.11). Alveoli consist of cells that line 
the duct and are responsible for milk production. Breast cancer is a malignant 
tumour that originates from the cells lining the ducts or lobules of the breast. It 
can invade nearby breast tissue and metastasise through the lymph nodes to 
the rest of the body (Kopans, 2007).  
Symptoms of breast cancer include (Jenkin, 2008):  
 Lumps, dimples or swelling in the breast 
 Nipple discharge, an inverted nipple or pain around the nipple. 
 Tenderness of the breast 
 Sudden prominent superficial veins. 
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Figure 1.11: Anatomy of the breast (Ross & Wilson, 1981).  
 
1.2.2 Risk factors 
Risk factors that may influence the onset of breast cancer include gender, age, 
ethnicity, age at menarche (Constantino, et al., 1999) genetic risk factors, 
environmental factors, dense breast tissue, hormone replacement therapy and 
hormonal changes (menstrual cycle and menopause) (Song, Lee & Kang, 
2010). Some other risks include obesity, alcohol consumption, diet, physical 
activity, oral contraceptives, nulliparity and late first full-term pregnancy 
(Chlebowski, et al., 2005; Song, Lee & Kang, 2010).  
Breast Cancer genes 1 and 2 (BRCA 1 & 2) are two of the main genes involved 
in dsb repair by HR, transcriptional regulation (Barwell, et al., 2007), DNA 
recombination and cell-cycle checkpoint control and are classified as tumour 
suppressor genes (Tutt & Ashworth, 2002). Mutations of these genes lead to 
truncated proteins and missense mutations inactivating their products which 
results in the misrepair of dsbs. In the general population group, 3 - 5 % will 
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have one of these mutated BRCA genes (Gerhardus, et al., 2007) and women 
who have these mutated BRCA genes have up to an 85 % chance of getting 
breast cancer by the age of 70 years (Tutt & Ashworth, 2002). 
 
1.2.3 Classification of tumours 
BC can be classified into several types such as Lobular Carcinoma in situ 
(LCIS), Ductal Carcinoma in situ (DCIS), Infiltrating Ductal Carcinoma (IDC), 
Infiltrating Lobular Carcinoma (ILC) and Paget’s disease of the nipple (Fraker, 
2004). If it is non-invasive, the cancer stays in the milk ducts or lobules of the 
breast (its originating point). If it is invasive / infiltrating, the cancer has 
metastasised past its originating point into the surrounding breast tissues. Most 
breast cancers are the latter. In this study, the following breast cancer types 
were most commonly seen: 
 
Infiltrating/ Invasive Ductal Carcinoma (IDC) - This is the most common type 
of breast cancer, accounting for approximately 80 % of all breast cancer cases. 
It is defined as cancer that has spread to the surrounding breast tissues 
through the milk ducts from where it originates (Fraker, 2004). 
Infiltrating/ Invasive Lobular Carcinoma (ILC) -This is the second most 
common type of breast cancer and occurs in 10 % of breast cancer cases. ILC 
is diagnosed when the cancer has spread from the lobules to the rest of the 
breast tissues (Fraker, 2004). 
Ductal Carcinoma in situ (DCIS) – DCIS is a non-invasive neoplastic 
proliferation of epithelial cells confined to the ductal-lobular system. This type 
accounts for approximately 10 % of all cases (Wiechmann & Keurer, 2008). 
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1.2.4 TNM Staging of tumours 
In 2001 the Breast Task Force revised the American Joint Committee of 
Cancer’s (AJCC) staging system for breast carcinoma. Consequently the 
tumour-node-metastasis (TNM) system was officially adopted in 2003. It is a 
system used to provide more details on the characteristics of the tumour. This 
is done by evaluating the extent of the primary tumor (T), regional lymph nodes 
(N), and distant metastases (M) and provides a ‘‘stage grouping’’ based on T, 
N, and M. The system is frequently updated due to technology always being 
upgraded (Edge, et al., 2010). The summary of the TNM system is shown in 
the table 1.1 below.  
Table 1.1: Adaptation of the recent TNM stage grouping for BC from the AJCC 
(Edge, et al., 2010) 
The final TNM stage grouping for BC 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 N1mi M0 
 T1 N1mi M0 
IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
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1.3  Radiosensitivity and Breast Cancer 
1.3.1 Radiotherapy 
RT is the medical use of ionising radiation as part of cancer treatment to control 
local malignant cells (LaTorre Travis, 2000). The aim of radiotherapy is to 
inactivate the tumour cells while minimising damage to the normal surrounding 
cells. The difficulty of this mode of treatment involves deciding on the most 
appropriate dose and fractionation scheme because patients vary considerably 
in their tumour and normal tissue responses (Borgmann, et al., 2008). 
 
For most patients at CMJAH radiation is delivered externally using high energy 
X-ray beams, which has an energy value measured in megavolts (MV). The 
international system of units of absorbed dose given to a patient is the gray 
(Gy) (World Health Organisation).  
In some cases, depending on the characteristics of the tumour, RT can be 
given in combination with other treatments such as surgery and chemotherapy. 
RT can be given before or after the other treatments. At CMJAH, it is often 
given after surgery and chemotherapy. Neoadjuvant chemotherapy is given 
when the patient is diagnosed at an advanced stage (stages III and IV) and 
used for systemic control while RT is used to achieve local control of the breast 
tumour post-surgery.  
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1.3.2 Clinical radiosensitivity 
Patients who display more side effects following RT may be classified as 
clinically radiosensitive. Side effects of radiation therapy can be acute or late 
effects. Acute RT effects include skin reactions, dyspnoea, difficulty swallowing, 
fatigue, nausea or loss of appetite. Mental side effects include insomnia, 
depression or concentration difficulties.  
Telangiectasia, hyperpigmentation, ulceration, swelling of the soft tissue 
(edema) in the breast and or arm (Barber, et al., 2000; Yi, et al., 2009), change 
in appearance and or shrinkage of the breast, difficulty in raising or moving the 
affected arm are all late effects that occur about 90 days post treatment 
(Sjovall, et al., 2009).  
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1.4 Aim  
This project was divided into two components. The first was to compare the 
chromosomal radiosensitivity between a group of breast cancer patients and 
healthy (cancer free) participants in a South African population.  
The second component of the study was to assess chromosomal 
radiosensitivity in BC patients before and after completion of radiation 
treatment. 
1.5  Research objectives 
1.  Compare chromosomal radiosensitivity in South African breast cancer 
patients with healthy (cancer free) individuals, using the micronucleus 
assay. 
2.  Correlate chromosomal radiosensitivity with clinical parameters, such as 
the tumour pathology and social parameters, such as age and ethnicity. 
3.  Compare the micronucleus frequency in breast cancer patients before and 
after radiotherapy. 
4. Investigate the origin of MN seen in breast cancer patients before and after 
radiation therapy using the Micronucleus-centromere assay. 
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2. Materials and Methods 
2.1 Sample collection 
Heparinised blood samples of breast cancer patients were collected at the 
CMJAH. A total of 97 samples were collected: 64 were patient samples and 33 
were from healthy individuals. The healthy control samples were obtained from 
student and staff members of the University of the Witwatersrand (WITS) 
Medical School and the CMJAH Radiation Oncology Department. The age 
range was between 28-82 years (mean = 56) for the BC patients and 21-62 
(mean = 31) for the healthy individuals. Age matching of patients and controls 
was attempted but not achieved due to the reduced age of staff members used 
primarily as controls. 
For the first component of the study, the radiosensitivity of 40 pre-surgery 
breast cancer patients, who had not received chemotherapy, was compared 
with that of 33 healthy individuals, who comprised the control group. Samples 
were collected at CMJAH and analysis was performed. For the second 
component of the study, radiosensitivity was compared between patients 
before RT and after completion of RT. Samples were collected and processed 
(MN Assay) at CMJAH and analysis was performed at a collaborative 
laboratory in the Department of Radiobiology, Ghent University in Belgium. In 
total, 24 patient samples were collected before and after the completion of their 
treatment. At the time of sampling, 8 of these patients had not had 
chemotherapy before, while the remaining 16 BC patients had. 
Written informed consent was obtained from each volunteer. Social data such 
as age group, ethnicity, gender, smoking habits and monthly income was 
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obtained from each volunteer, by using a questionnaire that they completed. 
Clinical information on the tumour pathology, medication and treatments (radio- 
and/or chemotherapy) was obtained from the patient files. 
The study was approved by the Human Research Ethics Committee, WITS; 
ethics number: M10372 (see Appendix). 
 
2.2 Methods 
2.2.1 The G0 Micronucleus assay 
Heparinised blood (0.5 ml), (left at room temperature for at least 30 minutes to 
allow for mixing of blood with anti-coagulants), and pre-warmed complete RPMI 
medium (4.5 ml) (see Appendix) were added to a sterile culture flask. The 
blood-medium mixture was either irradiated or sham irradiated. For irradiation, 
the culture flasks were placed in a Phantom-water tank. The distance from the 
culture flasks to the radiation source was 100 cm at an angle of 90 degrees. 
The field size was 10:10 and the Energy Value 6 MV using the Linac X-ray 
machine (Siemens). Each sample was irradiated with 3 different doses and 
each dose was done in duplicate (6 cultures). Samples were irradiated at either 
2 Gray (Gy) or 4 Gy respectively at a dose rate of approximately 1.33 Gy / min. 
A 0 Gy dose was used as a sham-irradiated control. The radiations were done 
at the Medical Physics Department in the Radiation Oncology Unit at CMJAH. 
 
The dose of 2 Gy was chosen since this is the dose given per fraction during 
conventional radiotherapy. To improve the sensitivity of the test when 
comparing radiosensitivity of patients with healthy donors, a dose of 4 Gy was 
given as this yield a higher level of induced chromosomal aberrations.  
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Immediately after irradiating the samples, 100 µl (1M/ml) PHA was added to the 
blood to stimulate the lymphocytes to divide and incubated at 37 oC, 5% CO2. 
To inhibit cytokinesis, 20 µl (1.5 µg/ml) Cyto B was added to the cultures 23 
hours later which were incubated further. The cells were harvested 70 hours 
after adding PHA, with a cold (4oC) hypotonic shock using 7 ml 0.075M KCl 
(see Appendix). This was done by transferring the culture to a 15 ml centrifuge 
tube and centrifuging for 8 minutes at 1000 rpms. The supernatant was taken 
off and KCl added slowly to the culture while vortexing. After centrifuging for 
another 8 minutes at 1000 rpms, the supernatant was discarded. The cells 
were fixed in methanol: acetic acid: Ringer solution (4:1:5) (see Appendix) to 
maintain the structure of the cells. The tubes with cells were stored overnight at 
4 oC.  
The next day, the cells were fixed again with a methanol: acetic acid (4:1) wash 
solution to increase the mechanical strength and stability of the cells. This step 
was repeated 2 - 3 times until the pellet was cleaned of remaining impurities. 
For slide preparation, the pellet was re-suspended in a few microlitres of 
methanol: acetic acid wash solution and 40 µl of the cell suspension dropped 
on a clean slide and allowed to spread across the slide.  
 
a) For automatic scoring, a drop of DAPI was placed on a slide and covered 
with a cover slip. The cells were then scanned by the automated 
microscope from MetaSystems using the DAPI filter and a 10 x objective. 
With DAPI, only the nuclei were stained blue. Slides were scanned at 
iThemba LABS in Cape Town. 
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b) For manual scoring, in the second component of our study, the cells were 
stained with Acridine Orange. The slides were placed in the Acridine 
Orange work solution (see Appendix) in a Coplin jar for 1 minute, rinsed in 
distilled water and then placed in the Acridine Orange buffer in another 
Coplin jar (see Appendix) for another minute. The slides were then 
removed from the Coplin jar and about 20 µl of the Acridine Orange buffer 
was dropped onto the slides.  
To prevent the cells from drying, cover slips were placed on top of the 
slides and rubber cement placed around the edge of the cover slips to seal 
it.  
The slides were scored using the DAPI triple filter with a 20 x objective 
using a Zeis Axioskop microscope. Acridine orange stained the nuclei 
green and the cytoplasm orange.  
 
Scoring criteria 
For manual scoring, the criteria of Fenech, et al., (2003) were followed: 
Only separate binucleated cells with nuclei in the same cytoplasmic boundary 
were counted (Figure 2.1 A). Overlapping nuclei had to be visibly separated by 
their nucleic boundary (Figure 2.1 B). The nuclei had to be approximately the 
same size and had to have a similar staining pattern and intensity. If the nuclei 
were joined by neoplasmic bridges (Figure 2.1 C, D), they could still technically 
be scored as binucleates, but in this study, they were excluded. 
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Figure 2.1: Different types of BN cells that can be scored (A - D). C & D contain neoplastic 
bridges that were excluded in this study (Fenech, et al., 2003). 
 
The scoring criteria for the MN, which are usually round or oval, required that it 
be separate from the nuclei. If the micronucleus overlapped with the nuclei, a 
clear boundary of the micronucleus needed to be visible. MN could be between 
1 / 16 to 1 / 3 the size of the main nuclei and each cell could contain one or 
more micronucleus. The staining intensity of the micronucleus had to be equal 
or greater than that of the main nuclei (Figure 2.2) (Fenech, et al., 2003).  
 
 
 
 
 
Figure 2.2: Different types of BN cells containing viable MN varying in sizes between a 1/16 to 
1/3 of the main nuclei (A - D) (Fenech, et al., 2003). 
 
For automatic scoring, the same criteria used for manual scoring were applied. 
The Metafer 4 software program (MetaSystems), which has an automated BN 
and MN scoring module (MNScore) was used. The software program has 
specific classifiers used to scan the slides and find BN cells containing similar 
sized nuclei. An additional classifier was also applied to search for MN with a 
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specific size, within a specified circular area surrounding the two nuclei 
(Schunck, et al., 2004). Images of each BN cell were taken using a digital 
camera attached to the microscope and placed in a gallery. Associated MN 
numbers were automatically recorded for each image, thus allowing a scorer to 
perform manual checks to ensure quality control.  
 
Table 2.1: Classifier settings used for the Metafer software program to score 
BN cells and MN: 
Classifier name: Ans MN Nov 2011 
Nuclei 
Object threshold 15 % Maximum distance 25 µm 
Minimum area 80.00 µm2 
Max area 
asymmetry 
80 % 
Maximum area 1000.00 µm2 
Region of interest 
radius 
30 µm 
Max reference 
concavity depth 
0.160 
Max object area in 
ROI 
35 µm2 
Max aspect ratio 1.370   
Imaging Processing Operations: Sharpen (3,4) 
 
Micronucleus 
Imaging Operations: Median V (3) Median H (3) Average (3,1) Sharpen (5,5) 
Object threshold 7 % 
Max reference 
concavity depth 
0.500 
Minimum area 1.00 µm2 Max aspect ratio 1.700 
Maximum area 40.00 µm2 
Maximum 
distance 
30 µm 
 
 
AutoSeperate 
A – Concavity regression radius 10/10 µm 
B – Concavity min contour angle 45 0 
C – Min concavity distance 40 % 
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2.2.2 The Micronucleus-centromere assay 
The micronucleus assay combined with the pancentromeric probe allows the 
differentiation between background MN and MN induced by radiation. For this 
study, the FISH pancentromeric probe was made using an optimised version of 
the nick translation method.  
 
2.2.2.1 The pancentromeric probe production 
1. DNA extraction 
A blood sample was collected from a male donor in an EDTA tube in order to 
obtain sequences from both the X and Y chromosomes with the purpose of 
amplifying the centromeric region. DNA was extracted using the QIAamp mini 
DNA blood kit (QIAgen), in which DNA is absorbed onto a silica-gel membrane, 
which is washed to remove contaminants, and the DNA released from the 
column using an elution buffer. The manufacturer’s protocol was followed: 
 
The EDTA tubes were centrifuged at 1500 rpms for 10 minutes. Approximately 
400 µl buffy coat was transferred into a 1.5 ml microcentrifuge tube containing 
40 µl QIAGEN proteinase K. To this, 400 µl of buffer AL was added, mixed by 
vortexing for 15 seconds and then left to incubate for 10 minutes at 56 0C to 
lyse the cells. After incubation, 400 µl of 100 % ethanol was added and mixed 
by pulse vortexing.  
The mixture was carefully applied to a QIAamp mini spin column and 
centrifuged at 8000 rpms for 1 minute. The collection tube was then discarded 
and the column placed in a new collection tube, to which 500 µl of wash buffer 
AW1 was added and the tube centrifuged again. The column was placed in a 
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new collection tube and 500 µl of wash buffer AW2 was added to the column 
and centrifuged at full speed (14000 rpms) for 3 minutes.  
The column was placed in another collection tube and spun for 1 minute to 
remove any residual buffer. The column was then placed in a 1.5 ml Eppendorf 
tube and 200 µl of elution buffer was added to the column. This was left to 
incubate at room temperature for 1 minute and centrifuged. The concentration 
of the extracted DNA was then measured with the NanoDrop 
Spectrophotometer. The extracted DNA was stored at - 20 0C. 
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2. Polymerase Chain Reaction (PCR) 
Centromeric DNA was amplified by PCR using primers that bind specifically to 
the centromeric DNA sequence. The whole procedure was done on ice. 
Table 2.2: Reagent concentrations and volumes used for the PCR reaction. 
Adapted from Weier, et al., (1991) 
Reagent [Stock] [Final] Amount 
DNA X ng/µl* 250 ng X µl * 
Forward primer 
(Bioline) 
5’ –GAA GCT TAA CTC 
ACA GAG TTG AA -3’  
100 µM 1.2 µM 1.2 µl 
Reverse primer 
(Bioline) 
5’ -GCT GCA GAT CAC 
AAA GAA GTT TC -3’  
100 µM 1.2 µM 1.2 µl 
10x NH4 reaction 
buffer (Bioline) 
10 x 1 x 10 µl 
MgCl2 (Bioline) 10 mM 1.6 mM 16 µl 
dNTP mix (Bioline) 10 mM 100 µM 1 µl 
BioTaqpolymerase 
(Bioline) 
5 U/µl 5 U 1 µl 
dH20 (Sabax)   Make up to 100 µl 
*DNA concentrations varied per sample Total: 100 µl 
 
PCR program: +95 0C, 10’ 
 +96 0C, 1’ 
 +45 0C, 1’ 
 +72 0C, 1’ 
 +72 0C, 5’ 
 +4 0C, ∞ 
 
30 x 
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The PCR reaction was done using the Eppendorf Thermal Cycler.  
To check if the PCR was successful, 5 µl of the PCR product was run on a 2 % 
agarose gel (see Appendix): 
A 6x Orange DNA loading dye was mixed with the PCR product as well as with 
the O’GeneRuler 100 bp DNA ladder. The products were pipetted into separate 
wells and run at a potential of 90 V for about 30 minutes. 
A successful PCR showed 2 bands with a monomeric fragment of 175 bp and a 
dimeric fragment of 345 bp when viewed under fluorescent light (Figure 2.3) 
(Weier, et al., 1991). 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: PCR showing centromeric sequenced products of 175 bp and 345 bp. P1 and P2 
indicates the PCR products and C indicates the negative control. The bottom bands in all lanes 
indicate primer dimers. 
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3. PCR purification 
The rest of the PCR product was purified, following a successful PCR reaction. 
This was done by using the Biospin PCR Purification Kit (BioFlux) and by 
following their protocol. 
 
The rest of the purified PCR product was transferred to a 1.5 ml Eppendorf 
tube and twice the volume of binding buffer was added to the PCR product and 
briefly vortexed. This was then applied to a column and centrifuged for 1 minute 
at 7500 rpms. The flow through was discarded and the column was placed in a 
new collection tube. Next, 650 µl of wash buffer was added to the column and 
the column centrifuged for 60 seconds at 10600 rpms, the flow through 
discarded again and the step repeated. The column was placed in a new 
collection tube and centrifuged again for 1 minute at 10600 rpms. The column 
was then placed into a 1.5 ml Eppendorf tube and 50µl of dH20 added to the 
column and incubated at room temperature for 1 minute. Thereafter, the tube 
was centrifuged for 1 minute at 10600 rpms and the concentration of the PCR 
product was checked using the NanoDrop Spectrophotometer.  
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4. Direct labelling of PCR product by nick translation method 
The centromeric DNA was directly labelled using the nick translation method, in 
which the DNase 1 enzyme makes single stranded breaks in the double 
strands of DNA. Polymerase 1 then removes nucleotides and adds 
fluorescently labelled ones with its exonuclease and endonuclease activity, 
resulting in fluorescently labelled DNA fragments that can be hybridised to the 
region of interest. 
 
Table 2.3: Reagent volumes for labelling method 
Reagent Volume 
NT buffer (Bioline) 10 µl 
β-mercaptoethanol (Sigma-
Aldrich) 
10 µl 
dNTP mix (with spectrum 
orange; ENZO) 
8 µl 
DNase I (Bioline) 
(Working solution) 
1 µl 
DNA polymerase I (Bioline) 3 µl 
DNA 1-2 µg 
dH20 (Sabax) Make up to 100 µl 
Total: 100 µl 
 *See Appendix for methods 
The products were pipetted into a PCR tube and placed in a thermal cycler for 
30 minutes at 15 0C and then immediately placed on ice.  
To check the size of the probe, 8 µl was denatured using the Eppendorf 
Thermal Cycler at 96 0C for 3 minutes and then immediately placed on ice. The 
8 µl of denatured probe was run on a 2 % agarose gel together with a 100 bp 
DNA ladder for about 30 minutes at 90 V. A smear of 200 – 500 bp was seen 
when viewed under fluorescent light (Figure 2.4). Fragments of this size are 
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small enough to penetrate the nuclear pore but large enough to avoid cross 
hybridisation during FISH. 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Direct labelling of the purified PCR products using nick translation, showing a 
smear between 200 – 500 bp. Bottom bands indicate unincorporated Spectrum Orange dUTPs 
 
5. Probe precipitation 
Enzymatic inactivation 
The probe mixture was transferred to a 1.5 ml Eppendorf tube and 3 µl 0.5 M 
Ethylenediaminetetraacetic acid (EDTA) and 1 µl 10 % Sodium Dodecyl Sulfate 
(SDS) was added to the probe mixture and placed in a heating block at 65 oC 
for 15 minutes while kept in the dark. Then 2 µl of Herring sperm DNA (binds to 
repetitive DNA to reduce non-specific binding of the probe) was added to the 
mixture followed by 10 % total volume of probe mixture 3 M NaAc3 and 2.5 X 
total volume of probe mixture ice cold 100 % ethanol and mixed well. The 
probe mixture was then stored at - 20 0C overnight. 
 
 
 
Smear between 200-
500 bp 
  Ladder           P1             P2 
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The next day, the tube was removed from the freezer and spun at 13000 rpms 
for 30 minutes at 4 oC. The supernatant was poured off and 200 µl of ice cold 
70 % ethanol was added to the tube to wash the pellet and centrifuged again 
for 13000 rpms for 10 minutes at 4 0C. The supernatant was poured off again 
and the pellet air dried for about 5 - 10 minutes while keeping it in the dark. The 
probe pellet was re-suspended in 60 µl of hybridisation buffer (see Appendix) 
and left on a shaker to allow the pellet to dissolve, after which it was stored at  
- 20 0C. 
 
2.2.2.2 Fluorescent in situ Hybridisation (FISH) using the pancentromeric 
probe 
Aging the slides 
Before commencement of the FISH assay, the slides were first aged to remove 
excess fixative from the cells. This was done by placing the slides in a 70 % - 
90 % - 100 % ethanol series for 5 minutes each in a Coplin jar and allowed to 
air-dry. 
1. Hybridisation 
The slides were denatured by placing them in the pre-heated denaturing 
solution (see Appendix) using a heat resistant Coplin jar, in a waterbath at  
76 0C for 5 minutes. Next, the slides were hydrated by placing them in an ice 
cold ethanol series of 70 % - 90 % - 100 % for 5 minutes each while shaking. 
To denature the probe, 8 µl per slide was aliquoted into a 1.5 ml Eppendorf 
tube and placed in the waterbath at 76 0C for 5 minutes, keeping it in the dark. 
It was then placed on ice and placed aside (keeping it in the dark). Next, 8 µl of 
the probe was pipetted on a coverslip and the slide placed on top. It was then 
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sealed with rubber cement, placed in a beaker with moist tissue paper, covered 
with foil and then placed in an incubator at 37 0C overnight. 
 
2. Washing the slides 
After removing the rubber cement, the coverslips were removed by allowing the 
slides to soak in a 50 % formamide and 20 x SSC solution for about 5 minutes 
to loosen the coverslips. The slides were then washed in 3 different Coplin jars 
containing 50 % formamide and 20 x SSC solutions at 45 0C for 10 minutes 
each, followed by a 2 x SSC solution for another 10 minutes and lastly in a 2 x 
SSC + Tween solution for 5 minutes. The slides were counterstained by placing 
a drop of DAPI onto the slides and covered with a coverslip. The slides were 
viewed using the MetaSystems microscope. 
 
Scoring criteria 
The same criteria for finding BN cells were used for automatic scoring of the 
FISH pancentromeric probe. The scorer reviewed all the cells in the image 
gallery and selected only those BN cells with MN for re-scanning using the 
Metafer Classifier Autocapt. The TRITC filter was used for the purpose of 
viewing the fluorescent signals of the stained centromeres of both the nuclei 
and centromere-containing MN with a 40 x objective. Images of the MN were 
captured and stored in another image gallery for distinguishing between CM- 
and CM+ MN. 
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2.3 Statistical Analysis 
GraphPad Prism 5 was used for statistical analysis. The Mann-Whitney and 
ANOVA one way tests were used at 95% confidence intervals.  
The sample size of this pilot study was based on other similar studies done in 
European populations. 
The Mann-Whitney test was used to compare micronucleus frequencies 
between the different groups of patients and healthy controls. This is a non-
parametric, or distribution-free test that is suitable to compare groups with small 
sample sizes where no underlying distribution can be assumed.  
The Wilcoxon test was used to compare the before and after RT micronucleus 
frequencies. This is a non-parametric test used to compare two related 
samples. 
The ANOVA test was used to compare more than one clinical or social 
parameter such as the ethnicity groups or tumour staging with the micronucleus 
frequencies. 
The coefficient of determination (R2) was used to determine the strength of the 
correlation between the BC patients and the healthy controls and their age.  
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3. Results 
For specific p values, see Appendix B 
3.1 Micronucleus assay comparing the radiosensitivity of non-treated 
breast cancer patients to healthy individuals 
For the first component of the study, the radiosensitivity of 40 pre-surgery 
breast cancer patients was compared with 33 healthy individuals, who 
comprised the control group. Not all the MN cultures set up from these 73 
donors were successful. In 25 % of the breast cancer patients and 9 % of the 
healthy individuals, the yield of the BN cells was insufficient for microscopic 
analysis. Only those samples where 500 BN cells could be scored were 
included in the study. It should be noted that the number of BN cells scored 
was generally lower in the BC group than in the healthy individuals, due to 
patient medication or immunological conditions that could have influenced cell 
survival rates.  
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Figure 3.1 shows the average of the spontaneous MN per 1000 BN cells for 
both studied population groups. The mean spontaneous micronucleus count 
was significantly higher for the BC patients (33 MN/ 1000 BN) compared to the 
healthy individuals (20 MN/ 1000 BN) (Mann-Whitney, p < 0.05). 
 
 
 
 
 
 
Figure 3.1: Mean of spontaneous micronucleus frequency of BC patients and the healthy 
control group (error bars =SEM). Values indicated = mean. 
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The radiation-induced micronucleus frequency was obtained by subtracting the 
spontaneous micronucleus frequency from the irradiated micronucleus 
frequency. No significant differences were noted when the radiation-induced 
micronucleus frequencies for the doses 2 Gy and 4 Gy were compared 
between BC patients [mean ± SEM (2 Gy: 193 ± 9; 4 Gy: 604 ± 30 MN/ 1000 
BN)] and healthy individuals [mean ± SEM (2 Gy: 197 ± 9; 4 Gy: 575 ± 24 MN/ 
1000 BN)] (Mann-Whitney, p > 0.05) (Figure 3.2). However, although not 
significant, the BC patients did show a slightly higher micronucleus frequency 
after 4 Gy.  
 
 
 
 
 
 
 
Figure 3.2: Mean of radiation-induced micronucleus frequency after 2 Gy and 4 Gy doses in 
vitro, when comparing BC patients with healthy individuals (error bars =SEM). Values indicated 
= mean. 
  
 
193 
604 
197 
575 
0
100
200
300
400
500
600
700
2 Gy 4 Gy
N
u
m
b
e
r 
 o
f 
M
N
 /
 1
0
0
0
 B
N
 c
e
lls
 
Mean of MN frequency after in vitro radiation 
BC patients
Healthy individuals
43 
 
To support the results observed in figure 3.2 where the BC patients were 
marginally more radiosensitive, the distribution of the 4 Gy micronucleus 
frequencies between the BC patients and healthy individuals were evaluated 
(Figure 3.3). No statistically significant difference was observed (Mann-
Whitney, p > 0.05). It was observed that the micronucleus values of the BC 
patients lay in the higher micronucleus frequency range indicating a slight 
increase in total chromosomal damage caused by radiation. 
 
 
 
 
 
 
 
Figure 3.3: Distribution of the radiation-induced micronucleus frequency after 4 Gy of BC 
patients and healthy individuals. 
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3.2 Correlation between clinical parameters and chromosomal 
radiosensitivity 
The age distribution of the BC patients used in this study is presented in figure 
3.4. The majority of BC incidences in our study occurred between the ages of 
41 and 80 years.  
 
 
 
 
 
 
Figure 3.4: The BC incidence rate per age group of our study.  
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3.2.1 Correlation between spontaneous MN and age 
No clear correlation between the spontaneous micronucleus frequency and age 
could be observed in the BC patients (R2 [BC patients] = 0.13) or the healthy 
control group (R2 [healthy controls] = 0.11) (Figure 3.5).  
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Correlation between the spontaneous micronucleus frequency and age in both BC 
patients and healthy controls.  
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3.2.2 Association between spontaneous MN and ethnic group 
The South African population is genetically very heterogeneous. The potential 
influence of ethnicity on the micronucleus frequency for both the BC patients 
and healthy participants was investigated. In the studied population group, 
most of the patients were either African (65 % of group) or white (24 % of 
group). The results showed that on average the white patients had a propensity 
towards a higher spontaneous micronucleus frequency [mean ± SEM (29 ± 3 
versus 24 ± 5 MN/ 1000 BN)] (Figure 3.6 a) as well as a higher induced 
micronucleus frequency compared to the African patients [mean ± SEM (2 Gy: 
219 ± 22 versus 192 ± 11; 4 Gy: 593 ± 35 versus 588 ± 29 MN/ 1000 BN)] 
(Figure 3.6 b), although the difference was not statistically significant (Mann-
Whitney, p > 0.05).  
Amongst the healthy control group, no significant differences in the 
spontaneous micronucleus frequency when correlating the ethnicity versus the 
micronucleus values were observed (Mann-Whitney, p > 0.05).  
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b 
Figure 3.6: a) Mean of the spontaneous micronucleus frequency per ethnic group of BC 
patients.  
b) Mean of the radiation-induced MN per ethnic group of BC patients (error bars =SEM). Values 
indicated = mean. 
 
3.2.3 Association between spontaneous MN and menopause 
The spontaneous micronucleus frequencies of pre- and post-menopausal 
patients were examined to determine if menopause may influence the 
micronucleus frequency (Pre (n) = 8; Post (n) = 32). It was noted that on 
average the post-menopausal patients had a lower spontaneous micronucleus 
yield (28 MN/ 1000 BN) than the pre-menopausal patients (37 MN/ 1000 BN) 
(Figure 3.7). However, this is not entirely conclusive due to the difference in 
group sizes.  
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Figure 3.7: Comparison of the spontaneous micronucleus frequency between the pre- and 
post-menopausal patient group (error bars =SEM). Values indicated = mean. 
3.2.4 Association of spontaneous MN and tumour pathology in BC 
patients 
The potential influence of the tumour pathological factors on the micronucleus 
frequency was examined. No significant difference in the micronucleus 
frequency with respect to the type of tumour (eg DCIS, IDC), size of the 
tumours or the number of nodes present was observed (ANOVA, p > 0.05).  
When the BC patients were divided into 3 groups according to the pathological 
staging of their tumours, a slight affinity towards an increased average of 
spontaneous MN with increasing stage was observed. In particular, it was 
noted that patients with a stage III tumour (23% of group) had a higher, but not 
statistically significant (ANOVA, p > 0.05), spontaneous micronucleus 
frequency (mean ± SEM = 34 ± 10) compared to patients with tumour stage I 
(27% of group; mean ± SEM = 24 ± 6) or stage II (17% of group; mean ± SEM 
= 24 ± 4) (Figure 3.8). There were no patients with stage 0 or IV.  
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Figure 3.8: Comparison of the spontaneous micronucleus frequency between BC patient 
groups with different pathological tumour staging (error bars =SEM). Values indicated = mean. 
 
No significant correlation could be found between the number of MN and the 
hormone markers, estrogen/ progesterone/ HER2 hormone receptor (ANOVA, 
p > 0.05). Only one patient in our group had triple negative BC. Interestingly 
this patient, despite being an isolated case, showed a higher frequency of 
spontaneous MN compared to the other BC patients with different hormonal 
marker receptor types.  
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3.3 The micronucleus frequency of BC patients before and after 
radiotherapy 
Blood samples from 8 patients who underwent RT without prior chemotherapy 
were included in this part of the study. The first blood sample was taken before 
initiation of RT and the second blood sample was taken immediately after 
completing the last fraction of RT. An average total dose of 40.05 Gy in 15 
fractions of approximately 2 Gy was given for an average of 3 weeks. 
Slides for each sample were stained with Acridine Orange and scored 
manually. Not unexpectantly, the number of spontaneous MN (without giving an 
in vitro radiation dose), in patients after completion of their treatment was 
significantly higher than prior to their therapy (30 MN/ 1000 BN versus 131 MN/ 
1000 BN; p < 0.05) (Figure 3.9).  
 
 
 
 
 
 
Figure 3.9: The total number of spontaneous MN in BC patients before and after RT (error 
bars= SEM). *Significantly different compared to before RT (P < 0.05). Values indicated = 
mean. 
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In addition, the before and after therapy samples were given an in vitro dose of 
2 Gy and 4 Gy respectively. As expected, the number of MN after 4 Gy (mean 
± SEM = 858 ± 16) was considerably higher than that of the 2 Gy (mean ± SEM 
= 291 ± 35) micronucleus results. It was noticed that there was a trend of a 
lower number of MN in the group that received RT (Figure 3.10), but this was 
not statistically significant (Wilcoxon, p > 0.05).  
 
 
 
 
 
 
 
Figure 3.10: The number of radiation-induced MN after 2 Gy and 4 Gy doses that were 
delivered in vitro to patient blood samples, obtained before and after RT (error bars = SEM). 
Values indicated = mean. 
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3.4 The Micronucleus-centromere assay using the FISH 
pancentromeric probe for patients before and after RT 
With this assay, the origin of the spontaneous MN before and after RT could be 
investigated by determining if they were caused by aneugens or clastogens. A 
total of 8 patients were investigated. The proportion of centromere negative 
(CM-) MN and centromere positive (CM+) MN was similar in patients before 
RT. After RT, although both centromeric micronucleus numbers had increased, 
the number of CM- was significantly higher (Wilcoxon, p < 0.05) than that of the 
CM+ MN (Figure 3.11).  
 
 
 
 
 
 
 
 
Figure 3.11: The mean CM- and CM+ MN obtained in lymphocytes of BC patients prior to and 
after RT (error bars =SEM). Values indicated = mean. 
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Figure 3.12 represents the number of centromeric MN in 3 individual patients to 
illustrate the high inter-individual variation in CM- MN and CM+ MN that can be 
seen amongst patients. These results could allow evaluation of individual 
radiosensitivity. Patients 1 and 3 showed higher micronucleus counts which 
could be interpreted as these patients being more sensitive to radiation. Patient 
3 had the highest number of CM+ MN before RT, which may be due to a higher 
chromosomal instability. This patient also showed higher number of CM- MN 
after RT. 
 
 
 
 
 
 
 
Figure 3.12: The number of CM- and CM+ MN for 3 individual BC patients before and after RT. 
Values indicated = mean. 
The majority of patients had neoadjuvant CT at CMJAH. It was decided to 
evaluate whether or not chemotherapy would have any influence on the 
micronucleus results. Samples with a very low total BN cell count (ie < 250 BN) 
were excluded. In total, 13 of the 16 samples had a good BN cell count. It was 
noted that patients who had CT (Figure 3.13) displayed a similar spontaneous 
micronucleus count as that of patients who did not have CT (Figure 3.11). 
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Neoadjuvant CT patients displayed a slightly higher spontaneous CM+ MN 
count than CM- MN before therapy. After the completion of their therapy, 
similar results were observed as that of the non-neoadjuvant CT patients, 
which was an increase in the total number of MN. However, it was noted that 
the total micronucleus frequency, before and after RT, was on average less for 
the neoadjuvant CT patients (CM- + CM+: before RT = 8 CM MN/ 1000 BN; 
after RT = 70 MN/ 1000 BN) compared to the non-neoadjuvant BC patients 
(CM- + CM+: before RT = 11 CM MN/ 1000 BN; after RT = 93 MN/ 1000 BN). 
This was, however, not statistically significant (Wilcoxon, p > 0.05). 
 
 
 
 
 
 
 
 
 
Figure 3.13: The average of the number of CM- and CM+ MN obtained in lymphocytes of BC 
patients who had received chemotherapy (error bars =SEM). Values indicated = mean. 
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4. Discussion 
The main purpose of this study was to assess whether South African breast 
cancer patients are more radiosensitive than healthy individuals as has been 
observed in various European studies (Jones, et al., 1995; Thierens, Vral & De 
Ridder, 1996; Scott, et al., 1998; Hoeller, et al., 2003; Baeyens, et al., 2005). 
The micronucleus assay was used to assess the chromosomal damage in the 
lymphocytes as this assay is an easy, non-laborious and reliable test to assess 
chromosomal radiosensitivity (Scott, et al., 1999; Gamulin, et al., 2010).  
We found that in our South African cohort, the mean spontaneous MN 
frequency for the BC patients was significantly higher than that of the healthy 
control group. This is in contrast to the work of Baeyens, et al., (2004) who did 
not find any significant difference in the spontaneous micronucleus frequency 
between European breast cancer patients and healthy controls. Our results did 
however coincide with Jones, et al., (1995); Scott, et al., (1998); Hoeller, et al., 
(2003) and Baeyens, et al., (2005) who observed similar results. 
The higher average number of the spontaneous micronucleus frequency in BC 
patients in our study could be explained by the difference in average age 
between the group of breast cancer patients and healthy individuals (BC 
patients mean = 56 yrs; healthy controls mean = 31 yrs). This is a limitation in 
our study. Thierens, et al., (2000) showed an age-dependant increase of 
0.58MN / year for healthy women. Gamulin, et al., (2010) also found a 
significant correlation between the age and the increase in occurrence of MN in 
breast cancer patients. Unfortunately we could not confirm a correlation when 
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we plotted the spontaneous MN versus age in our cancer or healthy control 
groups as the R2 values were too low to deduce conclusive results (Figure 3.5).  
When considering the age and ethnicity in the South African population, African 
BC patients were on average younger than the other ethnic groups studied. 
This could explain their lower spontaneous micronucleus values. The white BC 
patient group had the highest spontaneous micronucleus frequency. They were 
on average older, therefore this could explain their higher spontaneous 
micronucleus frequency.  
The in vitro induced micronucleus (2 Gy & 4 Gy) results showed no statistically 
significant difference between the BC patients and healthy individuals. This is in 
contrast to the enhanced chromosomal radiosensitivity observed in BC patients 
in European studies (Scott, et al., 1998, 1999; Terzoudi, et al., 2000; Riches, et 
al., 2001; Baeyens, et al., 2004, 2005). Although not significant, there was a 
trend toward the BC patients having higher micronucleus values. Possible 
reasons for the higher spontaneous micronucleus frequency and somewhat 
higher radiation-induced micronucleus frequency observed in blood 
lymphocytes of the BC patients could be as a result of defective cellular repair 
processes (Parshad, et al., 1996; Sterpone, et al., 2010) or a delay in the cell 
cycle checkpoint (Lavin, et al., 1994). This is similar to what Hu, et al., (2002) 
noticed, i.e. a delay in the G2 phase of lymphocyte cell cycles after irradiation 
of the BC patients.  
Studies that showed an enhanced chromosomal radiosensitivity in BC patients 
suggested that BC patients containing defective DNA repair mechanisms 
generally have more DNA damage after radiation and therefore could be more 
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prone to developing cancer. In support of this, Rigaud, et al., (1990 a, b) 
reported that a lower DNA repair efficiency was associated with an increased 
number of acentrics.  
The lack of significant differences between the in vitro radiation-induced MN of 
BC patients and that of healthy controls in our study could be explained by the 
genetic diversity of the South African population. To support this hypothesis of 
genetic diversity, the micronucleus values of the patients were correlated with 
the ethnicity of the patient. The white BC patients showed on average a higher 
micronucleus frequency than the African patients, suggesting a higher 
sensitivity to radiation, although this was not statistically significant. The healthy 
control group was also examined and no significant differences were detected 
between the different ethnic groups.  
The small cohort that was used for this study limits the detection of any small 
differences between the micronucleus frequency and the different South 
African ethnic groups. Therefore, a larger cohort will have to be collected and 
the micronucleus frequency investigated to determine any conclusive 
differences between the ethnicity groups (African, White, Coloured, Indian), 
especially as no previous studies on this subject could be found.  
The histology of the tumours was also examined. There was no significant 
difference in the spontaneous micronucleus frequency when comparing the 
different types of tumours (IDC, DCIS), grading of the tumours (1, 2, 3) or 
tumour size. There was, however, a slight correlation between the spontaneous 
micronucleus frequency and the tumour stages (I, II, III).  
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With regard to the pathological staging, patients with stage III tumours had a 
higher spontaneous micronucleus frequency than patients with tumour stages I 
or II. This was consistent with the results obtained from Scott, et al., (1999) who 
observed similar results.  
The potential influence of the hormone receptor markers on the micronucleus 
frequency was investigated and we observed that the triple negative BC patient 
(ER-, PR, HER2-), although an isolated case, had a higher spontaneous 
micronucleus frequency than the triple positive (ER+, PR+, HER2+) or positive / 
negative (eg: ER+, PR+, HER2-) BC patients. Given that triple negative BC is 
considered to be a more aggressive tumour, is more difficult to treat and has a 
higher rate of recurrence and mortality (Dent, et al., 2007; Reis-Filho & Tutt, 
2008), it is possible that these patients may be more genetically unstable, 
which may thus result in a higher spontaneous micronucleus frequency. A 
bigger sample size of triple negative BC patients will have to be collected to 
deduce conclusive results as this is solely a speculative assumption. 
When dividing the BC patients into pre- and post-menopausal groups, we found 
that the average spontaneous micronucleus frequency of the pre-menopausal 
BC patients was on average 25 % higher than that of the post-menopausal BC 
patients. In literature there are some hypotheses that estradiol, which is present 
in higher concentrations in pre-menopausal women, might act as a direct 
clastogenic agent and this may explain the higher micronucleus frequency in 
pre-menopausal women (Dhillon & Dhillon, 1995; Ahmad, et al., 2000). Jung 
(2001) found that post-menopausal females had a lower risk of getting breast 
cancer due to an enhanced rate of cell death caused by aging and a reduced 
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cell proliferation rate. Therefore, a decrease in RS would be suspected as cells 
that may contain more DNA damage would have been killed off, resulting in 
less chromosomally unstable cells. This could explain our results as well as 
that of the correlation between age and the micronucleus frequency discussed 
earlier. A bigger cohort would however need to be acquired to deduce any 
conclusive results. 
When comparing the spontaneous micronucleus frequency in patients before 
and after radiotherapy, the results showed that the number of MN after RT was 
much higher than before therapy. Despite the small sample size, this confirms 
the study of Rigaud, et al., (1990 a), which demonstrated that RT induces 
chromosome aberrations such as dicentrics and acentric fragments in 
circulating lymphocytes. After the samples were given an additional 2 Gy or  
4 Gy dose in vitro, it was noted that the number of BN cells as well as MN after 
therapy was slightly lower than the pre-therapy samples for both doses 
although these differences were not statistically significant. These results were 
in agreement with those reported by Rigaud, et al., (1990 b) who found a 
decreased number of acentric fragments post RT. Possible reasons could be 
due to the saturation effect, cells undergoing necrosis / apoptosis due to 
irreparable damage or the adaptive response which involves the selective 
killing of lymphocytes with reduced DNA repair efficiency. 
The combination of the FISH with a pancentromeric probe with the 
micronucleus assay was done to distinguish between aneugenic and 
clastogenic damage. An increase in the spontaneous MN formed by whole 
chromosomes (CM+ MN) could be the result of chromosomal instability. When 
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comparing the average number of spontaneous MN with the pancentromeric 
probe in patients before radiation therapy, a similar number of CM+ MN and 
CM- MN were observed. Yet when we looked at the individual patient values, it 
was noted that one patient (patient 3; Figure 3.12) had a higher percentage of 
CM+ MN. This could indicate a greater chromosomal instability for this patient, 
which can be supported by the observation that the total micronucleus 
frequency after RT was also the highest in this patient. When comparing all the 
samples, the CM+ micronucleus frequency had increased after RT, but the CM- 
micronucleus frequency had increased more significantly. Our CM- MN results 
after RT compared well with the study of Vral, Thierens & De Ridder (1997), 
which showed that radiation induces more acentric fragments and therefore 
more CM- MN.  
In our population group, many BC patients went for chemotherapy prior to 
surgery, because the majority was diagnosed with late stage, large tumours 
and node positive BC. The number of centromeric MN was studied in patients 
who had neoadjuvant chemotherapy to see if CT influenced radiosensitivity 
assessment. It was noted that lymphocyte stimulation was less successful in 
this group of patients possibly due to prior damage caused by CT. No 
statistically significant difference was observed but the total number of MN 
scored was 26 MN/ 1000 BN less compared to the non-chemo group. Samples 
obtained prior to therapy, had on average slightly more CM+ MN than CM- MN 
compared to the patients who did not go for CT, but no significant differences 
were observed. The higher number of spontaneous CM+ MN is thought to be 
due to the genotoxicity of CT. Attia, et al., (2009) observed that although 
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chemotherapeutic agents to a larger part had clastogenic properties, it also, to 
a lesser extent, had aneugenic properties. 
According to Rigaud, et al., (1990 b), the accumulation of damage in the cells, 
due to the genotoxic effects of RT as well as CT could have led to apoptosis or 
to an adaptive response. A possible weakening of lymphocytes by CT could 
have induced a preferential killing or a reduced ability to respond to PHA 
stimulation due to greater irreparable damage after RT, resulting in the cells’ 
inability to divide, which may explain the lower total number of stimulated 
lymphocytes (Rigaud, et al., 1990 a).  
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Conclusion 
From the results obtained, it appears that breast cancer patients in South Africa 
show a trend to be more sensitive to radiation than the healthy control group. 
However, their sensitivity was not significant possibly due to their diverse 
genetic background. This however needs to be confirmed with a larger study 
group. 
Regarding the number of MN before and after RT, it was found that on average 
there was a higher micronucleus frequency in specimens collected after RT. 
This was expected as the radiation would cause damage to the cells. When the 
centromeric micronucleus assay with the FISH pancentromeric probe was used 
to look at the type of damage done to the chromosomes, it was noted that 
these patients had a higher number of CM- MN than CM+ MN after RT. This 
showed that they had obtained more clastogenic damage, which thus indicated 
that radiation causes more CM- MN. In the group of BC patients who received 
chemotherapy, similar results were observed as that of the non-chemo 
patients. However, the total number of cells cultured was on average less and 
the average number of CM+ MN (before RT), although not significant, was 
slightly higher, which can be explained by the aneugenic action of 
chemotherapy.  
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Future studies: 
Due to the difficulty in obtaining samples from patients who did not have 
chemotherapy prior to RT and due to lymphocyte stimulation problems, further 
research will have to be done to assess RS using a bigger cohort to measure 
the micronucleus frequency immediately after the patient had completed her 
treatment and over a period of time post-therapy (3, 6 or 12 months after RT). It 
may also be of interest to look at the repair mechanisms of breast cancer 
patients in order to assess if the South African population might have different 
repair mechanisms, given its genetic diversity, compared to a European 
population. With regard to the radiosensitivity versus ethnicity of BC patients, it 
would be interesting to look at the micronucleus frequency, especially in 
coloured BC patients as this is the third biggest ethnic group in South Africa. A 
bigger cohort of different ethnic groups will have to be collected. Additionally, a 
bigger cohort of triple negative BC patients will have to be collected to establish 
if these BC patients are more RS compared to the other BC sub-types. 
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Appendix A 
List of products: 
Micronucleus assay: 
Culture flasks: Greiner bio-one 
 
Phytohaemagglutinin (Sigma):  25 mg PHA + 25 ml dH2O  
 
Cytochalasin B (Sigma):  5 mg Cyto B + 3.3 ml DMSO  
 
Complete medium:  500 ml RPMI-1640 with L-glutamine  
 (Gibco)  
 5 ml penicillin/ streptomycin  
 (10 000 U/ml +10 000 µg/ml)  
 (Invitrogen)  
 75 ml Foetal Calf Serum (FCS) (Gibco) 
 
Ringer:  9 g NaCl (Merck)  
 0.42 g KCl (Merck)  
 0.24 g CaCl2 (Merck)  
 1L dH2O  
KCl:  5.6 g KCl (Merck)  
 1L dH2O 
 
Fixative for harvesting:  Methanol/ Acetic acid/ Ringer (4/1/5,  
 4 0C) (Merck) 
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Fixative for washing:  Methanol/ Acetic acid (4/1, 4 0C) 
 (Merck) 
 
Acridine Orange Staining: 
Stock solution: 0.1 g acridine orange stain 
 100 ml dH2O 
 
Acridine Orange Buffer: 1 buffer tablet 
 1L dH2O 
 pH = 6.8 
 
Acridine Orange work solution: 0.4 ml stock solution 
 + 40 ml Acridine Orange buffer 
 
Acridine Orange buffer: 40 ml Acridine Orange buffer 
 
Rubber cement Fixogum (Marabu) 
DAPI Staining: 
DAPI (4',6-diamidino-2-phenylindole): Vectashield 
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Pancentromeric probe method: 
A: PCR 
MgCl2 (10 mM): 10 µl 50 mM MgCl2 
 40 µl dH2O 
dNTP mix:   
Reagent Volume 
dATP (10 mM) 1.5 µl 
dCTP (10 mM) 1.5 µl 
dGTP (10 mM) 1.5 µl 
dTTP (10 mM) 0.75 µl 
dH2O 24.75 µl 
Total: 30 µl 
 
PCR Purification kit: Biospin PCR Purification Kit (BioFlux) 
 
B: Labelling of PCR by nick translation & probe precipitation 
 Nick translation (NT) buffer: 500 µl 1M Tris-HCl 
  100 µl 0.50M MgCl2 
  50 µl 10 mg/ml BSA 
  350 µl dH2O 
 Total: 1000 µl 
 
β-mercaptoethanol (0.1M): 0.1 ml β-mercaptoethanol (Sigma- 
 Aldrich) 
 14.4 ml dH2O 
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dNTP mix (Spectrum Orange):    
Reagent Volume 
dATP (10 mM) (BioRad) 1.5 µl 
dCTP (10 mM) (BioRad) 1.5 µl 
dGTP (10 mM) (BioRad) 1.5 µl 
dTTP (10 mM) (BioRad) 0.75 µl 
Spectrum Orange dUTP (1 mM)  7.5 µl 
dH2O 17.25 µl 
Total: 30 µl 
 
Spectrum Orange (1 mM) (ENZO): 50 mMol + 50 µl dH2O 
 
DNase I stock solution (stored at -20 0C): 3 mg DNase I (Roche) 
 0.5 ml 0.3 M NaCl  
 0.5 ml glycerol 
 
DNase working solution (always made fresh): 0.5 µl of DNase I stock solution 
 in 1 ml of ice cold dH20 
 
Hybridisation buffer (25 ml): 12 ml deionised formamide (100 %;  
 Merck) 
(stored at -20 0C) 2.5 ml 20 x SSC 
 2.5 g dextran sulphate 
 0.195 g sodium dihydrogen  
 Orthophosphate (Merck) 
 dH2O up to 25 ml 
 pH = 7  
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EDTA (0.5 M): 186.1 g EDTA Disodium Salt Dihydrate  
 (Merck) 
 1L dH2O 
 pH = 8 
SDS (10 %): 10 g SDS (Merck) 
 100 ml dH2O 
 
NaAc3 (3 M): 24.609 g Sodium acetate (Merck) 
 100 ml dH2O  
 
Herring Sperm DNA (Promega): 10 mg/ml  
 
10 x TBE buffer: 108 g Tris (Merck) 
 55 g boric acid (Merck) 
 40 ml 0.5 M EDTA (pH = 8) 
 1L dH2O 
 
1 x TBE buffer: 100 ml 10x TBE + 900 ml dH2O 
 
Agarose gel (2 %): 1.2 g agarose (1 g/100 ml 1 x TBE)  
 (Invitrogen) 
 60 ml 1 X TBE  
 6 µl GelRed (1 µl /10 ml) (Biotium) 
 
O’Gene Ruler 100 bp ladder (Fermentas) 
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C: FISH technique 
20 x SSC: 87.5 g NaCl (Merck) 
 44.1 g triNaCitrate (Merck) 
 500 ml dH2O 
 pH = 7  
 
Deionised formamide (per 100 ml): 1 spatula Analytical grade mixed bed  
 Resin (BIORAD) to formamide (Merck). 
 Stir for 2 hrs and filter with no. 1 filter  
 paper.  
 Store at 4 0C. 
 
Denaturing solution:  35 ml deionised formamide 
 5 ml phosphate buffer 
 5 ml 20 x SSC 
 5 ml dH2O 
 pH = 7  
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Phosphate buffer:   
Solution A (acid):  KH2PO4 (Merck) - 4.54 g / 500 ml 
 pH 4.51 
Solution B (base):  Na2PO4 (Merck) – 5.94 g / 500 ml  
 pH 8.97 
Phosphate buffer (in 100 ml):  41.3 ml solution A + 58.7 ml solution B 
 pH = 7 
50 % formamide (per 150 ml): 15 ml 20 X SSC 
 65 ml dH2O 
 70 ml formamide (Merck) 
 pH = 7  
 
Washing solution: 5 ml of 20 X SSC + 45 ml dH2O 
 
Tween washing solution:  5 ml of 20 X SSC + 45 ml dH2O + 
 25 µl Tween 20 (Merck) 
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Appendix B 
List of p values for compared micronucleus frequencies 
Sample Statistical test 
P value (95% 
confidence 
interval) 
Healthy 
participants vs BC 
patients (0 Gy) 
Mann Whitney 0.048 
Healthy 
participants vs BC 
patients (2 Gy) 
Mann Whitney 0.1010 
Healthy 
participants vs BC 
patients (4 Gy) 
Mann Whitney 0.7464 
African vs white 
BC patients 
Mann Whitney 0.2346 
African vs white 
BC patients  
(2 Gy) 
Mann Whitney 0.68 
African vs white 
BC patients  
(4 Gy) 
Mann Whitney 1 
Pre vs Post- 
menopausal 
Mann Whitney 0.5370 
Path. Stages (I, II, 
III) 
One-way ANOVA 0.5890 
Before vs after RT Wilcoxon 0.0381 
Before vs after RT 
(2 Gy) 
Wilcoxon 0.2316 
Before vs after RT 
(4 Gy) 
Wilcoxon 0.9969 
CM – before vs 
after RT 
Wilcoxon 0.0007 
CM + before vs 
after RT 
Wilcoxon 0.0249 
CT vs non CT Mann Whitney 0.5614 
 
  
72 
 
Appendix C 
 
 
 
73 
 
References 
Ahmad, M., Shadab, G. & Hoda, A., et al. 2000. Genotoxic effects of estradiol 
-17(beta) on human lymphocyte chromosomes. Mutat Res, vol. 466, pp. 109-
115 
 
Amend, K., Hicks, D. & Ambrosone, C. 2006. Breast cancer in African-
American women: Differences in tumor biology from European-American 
women. Cancer Res, vol. 66, pp. 8327-8330 
 
The American Cancer Society (ACS). 2011: Breast Cancer facts and figures, 
2011-2012. Atlanta, GA: American Cancer Society, pp. 1-16 
 
Attia, S., Aleisa, A. & Bakheet, S., et al. 2009. Molecular cytogenetic 
evaluation of the mechanism of micronuclei formation induced by 
Camptothecin, Topotecan, and Irinotecan. Environ Mol Mutagen, vol. 50, pp. 
145-151 
 
Baeyens, A., Thierens H. & Claes K., et al. 2002. Chromosomal 
radiosensitivity in breast cancer patients with a known or putative genetic 
predisposition. Br J Cancer, vol. 87, pp. 1379-1385 
 
Baeyens, A., Vandenbulcke, K. & Philippe J., et al. 2004. The use of IL-2 
cultures to measure chromosomal radiosensitivity in breast cancer patients. 
Mutagenesis, vol. 19, pp. 493-498 
 
74 
 
Baeyens, A. In vitro chromosomal radiosensitivity in breast cancer patients. 
[PhD Thesis], Ghent (Belgium): Ghent University, 2005, pp 3-19 
 
Baeyens, A., van den Broecke, R. & Makar, A., et al. 2005. Chromosomal 
radiosensitivity in breast cancer patients: Influence of age of onset of the 
disease. Oncol Rep, vol. 13, pp. 347-353  
 
Baeyens, A., Slabbert, J.P. & Willem, P., et al. 2010. Chromosomal 
radiosensitivity of HIV positive individuals. Int J Radiat Biol, vol. 86, pp. 584-592 
 
Barber J., Burrill, W. & Spreadborough, A., et al. 2000. Relationship between in 
vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the 
expression of normal tissue damage following radiotherapy for breast cancer. 
Radiother Oncol, vol. 55, pp. 179-186 
 
Barwell, J., Pangon, L. & Georgiou, A., et al. 2007. Lymphocyte radiosensitivity 
in BRCA1 and BRCA2 mutation carriers and implications for breast cancer 
susceptibility. Int J Cancer, vol. 121, pp. 1631-1636 
 
Borgmann, K., Hoeller, U. & Nowack S., et al. 2008. Individual radiosensitivity 
measured with lymphocytes may predict the risk of acute reaction after 
radiotherapy. Int J Radiat Oncol Biol Phys, vol. 71, pp. 256-264 
 
75 
 
Bryant, P. 1998. The Signal Model: a possible explanation for the conversion of 
DNA double strand breaks into chromatid breaks. Int J Radiat Biol, vol. 73, pp. 
243-251 
 
Bryant, P., Riches, A. & Terry, S. 2010. Mechanisms of the formation of 
radiation-induced chromosomal aberrations. Mutat Res, vol. 701, pp. 23-26 
 
Chlebowski, R., Chen, Z. & Anderson, G., et al. 2005. Ethnicity and breast 
cancer: Factors influencing differences in incidence and outcome. J Natl 
Cancer Inst, vol. 97, pp. 439–448  
 
Constantino, J., Gail, M. & Pee, D., et al. 1999. Validation studies for models 
projecting the risk of invasive and total breast cancer incidence. J Natl Cancer 
Inst, vol. 91, pp. 1541-1548 
 
Darroudi, F. 2008. Cytogenetic biological biodosimetry past, present and future 
perspectives. Abstract for the 12th International Congress of the International 
Radiation Protection Association  
 
Dent, R., Trudeau, M. & Pritchard, K., et al. 2007. Triple-Negative Breast 
Cancer: Clinical features and patterns of recurrence. Clin Cancer Res, vol. 13, 
pp. 4429-4434 
 
76 
 
De Ruyck, K., Van Eijkeren, M. & Claes, K., et al. 2005. Radiation-induced 
damage to normal tissues after radiotherapy in patients treated for 
gynaecologic tumours: association with single nucleotide polymorphisms in 
XRCC1, XRCC3 and OGG1 genes and in vitro chromosomal radiosensitivity in 
lymphocytes. Int J Radiat Oncol Biol Phys, vol. 62, pp. 1140-1149 
 
Dhillon, V. & Dhillon, I. 1995. Genotoxicity evaluation of estradiol. Mutat Res, 
vol. 345, pp. 87-95 
 
Edge, S., Byrd, D. & Compton, C., et al. 2010. AJCC cancer staging manual. 
7th ed., New York, NY: Springer. p. 130 
 
Fraker, T. 2004. Diagnosis and staging, In: Dow, K. ed. Contemporary issues in 
Breast Cancer: A nursing perspective. 2nd ed, London: Jones and Bartlett 
Publishers, pp. 58-77 
 
Fenech, M. 2000. The in vitro micronucleus technique. Mutat Res, vol. 455, pp. 
81-95 
 
Fenech, M., Chang, W. & Kirsch-Volders, M., et al. 2003. HUMN project: 
detailed description of the scoring criteria for the cytokinesis-block 
micronucleus assay using isolated human lymphocyte cultures. Mutat Res, vol. 
534, pp. 65-75 
77 
 
Gamulin, M., Garaj-Vrhovac, V. & Kopjar, N., et al. 2010. DNA and cytogenetic 
damage in white blood cells of postmenopausal breast cancer patients treated 
with radiotherapy. J Environ Sci Health Part A, vol. 45, pp. 292-304 
 
Gerhardus, A., Schleberger, H. & Schlegelberge B., et al. 2007. Diagnostic 
accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a 
systematic review. Eur J of Hum Genet, vol. 15, pp. 619-627 
 
Hall, E. & Giaccia, A. 2012. Radiobiology for the Radiologist. 7th ed. 
Philadelphia: Lippincott Williams & Wilkins, p. 3-11 
 
Hoeijmakers, J. 2001. Genome maintenance mechanisms for preventing 
cancer. Nature, vol. 411, pp. 366-374 
 
Hoeller, U., Borgmann, K. & Bonacker, M., et al. 2003. Individual 
radiosensitivity measured with lymphocytes may be used to predict the risk of 
fibrosis after radiotherapy for breast cancer. Radiother Oncol, vol. 69, pp. 137-
144 
 
Houtgraaf, J., Versmissen, J. & van der Giessen, W. 2006. A concise review of 
DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc 
Med, vol. 7, pp. 165-172 
 
78 
 
Hu, J., Smith, T. & Miller M., et al. 2002. Genetic regulation of ionizing radiation 
sensitivity and breast cancer risk. Environ Mol Mutagen, vol. 39, pp. 208-215 
 
Iarmarcovai, G., Botta, A. & Orsiére, T. 2006. Number of centromeric signals in 
micronuclei and mechanisms of aneuploidy. Toxicol Lett, vol. 166, pp. 1-10 
 
Jackson, S. & Bartek, J. 2009. DNA-damage response in human biology and 
disease. Nature, vol. 461, pp. 1070-1078 
 
Jenkin, R. 2008. Cancer, Breast. In: Horobin W. ed. Diseases and Disorders. 
New York: Marshall Canvendish Corporation, pp. 144–147 
 
Joiner, M., van der Kogel, A. & Steel, G. 2009. Introduction: the significance of 
radiobiology and radiotherapy for cancer treatment, In: Joiner, M. & van der 
Kogel, A. eds. Basic Clinical Radiobiology. 4th ed. London: Arnold, pp. 1–10 
 
Jones, L., Scott, D. & Cowan, R., et al. 1995. Abnormal radiosensitivity of 
lymphocytes from breast cancer patients with excessive normal tissue damage 
after radiotherapy: chromosome aberrations after low dose-rate irradiation. Int J 
Radiat Biol, vol. 67, pp. 519-528 
 
Jung, H. 2001. Is there a real risk of radiation-induced breast cancer for 
postmenopausal women? Radiat Environ Biophys, vol. 40, pp. 169-174 
79 
 
Kanaar, R., Hoeijmakers, J. & van Gent, D. 1998. Molecular mechanisms of 
DNA double-strand break repair. Trends Cell Biol, vol. 8, pp. 483-489 
 
Kopans, D. 2007. Breast Anatomy and Basic Histology, Physiology and 
Pathology. In: Breast Imaging, 3rd ed. Philadelphia: Lippincott Williams and 
Wilkins, pp. 7-43 
 
LaTorre Travis, E. 2000. Primer of Medical Radiobiology. 2nd ed. Chicago: Year 
Book Medical Publishers, pp. 23-58 
 
Lavin, M., Bennett, I. & Ramsay, J., et al. 1994. Identification of a potentially 
radiosensitive subgroup among patients with breast cancer. J Natl Cancer Inst, 
vol. 86, pp. 1627-1634 
 
Norppa, H. & Falck, G. 2003. What do human micronuclei contain? 
Mutagenesis, vol. 18, pp. 221-233 
 
National Cancer Registry (NCR) - The 2004 NCR Report 
Available at: 
http://www.cansa.org.za/cause_data/images/1056/Cancer_Registry_2004.pdf 
(Accessed: May 2012) 
 
80 
 
Parshad, R., Sanford, K. & Jones, G. 1983. Chromatid damage after G2 phase 
x-irradiation of cells from cancer prone individuals implicates deficiency in DNA 
repair. Proc Natl Acad Sci, vol. 80, pp. 5612-5616 
 
Parshad, R., Price, F. & Bohr, V., et al 1996. Deficient DNA repair capacity, a 
predisposing factor in breast cancer. Br J Cancer, vol. 74, pp. 1-5 
 
Reis-Filho, J. & Tutt, A. 2008. Triple negative tumours: a critical review. 
Histopathology, vol. 52, pp. 108–118  
 
Riches, A., Bryant, P. & Steel, C., et al. 2001. Chromosomal radiosensitivity in 
G2-phase lymphocytes identifies breast cancer patients with distinctive tumour 
characteristics. Br J Cancer, vol. 85, pp. 1157-1161 
 
Rigaud, O., Guedeney, G. & Duranton, I., et al. 1990a. Genotoxic effects of 
radiotherapy and chemotherapy on the circulating lymphocytes of breast 
cancer patients. I. Chromosome aberrations induced in vivo. Mutat Res, vol. 
242, pp. 17-23 
 
Rigaud, O., Guedeney, G. & Duranton, I., et al. 1990b. Genotoxic effects of 
radiotherapy and chemotherapy on the circulating lymphocytes of breast 
cancer patients. II. Alteration of DNA repair and chromosome radiosensitivity. 
Mutat Res, vol. 242, pp. 25-35 
81 
 
Ross, J. & Wilson, K. 1981. Foundations of Anatomy and Physiology. 5th ed. 
New York: Churchill Livingstone Inc, p. 236 
 
Sanford, K., Parshad, R. & Gantt, R., et al. 1989. Factors affecting and 
significance of G2 chromatin radiosensitivity in predisposition to cancer. Int J 
Radiat Biol, vol. 55, pp. 963-981 
 
Schunck, C., Johannes, T. & Varga, D., et al. 2004. New developments in 
automated cytogenetic imaging: unattended scoring of dicentric chromosomes, 
micronuclei, single cell gel electrophoresis, and fluorescence signals. 
Cytogenetic and genome research, vol. 104, pp. 383-389 
 
Scott. D., Spreadborough, A. & Levine, E., et al. 1994. Genetic predisposition in 
breast cancer. Lancet, vol. 344, p. 1444 
 
Scott, D., Barber, J. & Levine, E., et al. 1998. Radiation-induced micronucleus 
induction in lymphocytes identifies a high frequency of radiosensitive cases 
among breast cancer patients: a test for predisposition? Br J Cancer, vol. 77, 
pp. 614-620 
 
Scott, D., Barber, J. & Spreadborough, A., et al. 1999. Increased chromosomal 
radiosensitivity in breast cancer patients: a comparison of two assays. Int J 
Radiat Biol, vol. 75, pp. 1-10 
 
82 
 
Sjovall, K., Strombeck, G. & Lofgren, A., et al 2009. Adjuvant radiotherapy of 
women with breast cancer – Information, support and side-effects. Eur J of 
Oncol Nurs, vol. 14, pp. 147-153 
 
Song, M., Lee, K. & Kang, D. 2010. Breast Cancer Prevention Based on Gene–
Environment Interaction. Mol Carcinogen, vol. 50, pp. 280-290 
 
Sterpone, S., Cornetta, T. & Padua, L., et al. 2010. DNA repair capacity and 
acute radiotherapy adverse effects in Italian breast cancer patients. Mutat Res, 
vol. 684, pp. 43-48 
 
Terzoudi, G., Jung, T. & Hain, J., et al. 2000. Increased chromosomal 
radiosensitivity in cancer patients: the role of cdk1/ cyclin-B activity levels in the 
mechanisms involved. Int J Radiat Biol, vol. 76, pp. 607-615 
 
Thierens, H., Vral, A. & De Ridder, L. 1996. Cytogenetic study of radiological 
workers: effect of age, smoking and radiation burden on the micronucleus 
frequency. Mutat Res, vol. 360, pp. 75-82 
 
Thierens, H., Vral, A. & Morthier, R., et al. 2000. Cytogenetic monitoring of 
hospital workers occupationally exposed to ionising radiation using the 
micronucleus centromere assay. Mutagenesis, vol. 15, pp. 245-249 
 
83 
 
Thierens, H. & Vral, A. 2009. The micronucleus assay in radiation accidents. 
Ann Ist Super Sanita, vol. 45, pp. 245-249 
 
Tubiana, M. & Dutreix, J. 1990. Introduction to Radiobiology. London: Taylor 
and Francis 
 
Turnbill, G., Mirugaesu, N. & Eeles, R. 2006. Radiotherapy and genetic 
predisposition of breast cancer. Clin Oncol, vol. 18, pp. 257-567 
 
Tutt, A. & Ashworth, A. 2002. The relationship between the roles of BRCA 
genes in DNA repair and cancer predisposition. Trends Mol Med, vol. 8, pp. 
571-576 
 
Varga, D., Johannes, T. & Jainta, S., et al. 2004. An automated scoring 
procedure for the micronucleus test by image analysis. Mutagenesis, vol. 19, 
pp. 391-397 
 
Vral, A., Thierens, H. & De Ridder, L. 1997. In vitro micronucleus-centromere 
assay to detect radiation-damage induced by low doses in human lymphocytes. 
Int J Radiat Biol, vol. 71, pp. 61-68 
 
84 
 
Vral, A., Fenech, M. & Thierens, H. 2011. The micronucleus assay as a 
biological dosimeter of in vivo ionising radiation exposure. Mutagenesis, vol. 
26, pp. 11-17 
 
Weier, H., Lucas, J. & Poggensee, M., et al. 1991. Two-color hybridisation with 
high complexity chromosome-specific probes and a degenerate alpha satellite 
probe DNA allows unambiguous discrimination between symmetrical and 
asymmetrical translocation. Chromosoma, vol. 100, pp. 371–376. 
 
West, C., Davidson, S. & Elyan, S., et al. 2001. Lymphocyte radiosensitivity is a 
significant prognostic factor for morbidity in carcinoma of the cervix. Int J Radiat 
Oncol Biol Phys, vol. 51, pp. 10-51 
 
Wiechmann, L. & Keurer, H. 2008. The molecular journey of ductal carcinoma 
in situ to invasive breast cancer. Cancer, vol. 112, pp. 2130–2142 
 
Wouters, B. & Begg, A. 2009. Irradiation-induced damage and the DNA 
damage response, In: Joiner, M. & van der Kogel, A .eds. Basic Clinical 
Radiobiology. 4th ed. London: Arnold, pp. 11–26 
 
Wouters, B. 2009. Cell death after irradiation: how, when and why cells die, In: 
Joiner, M. & van der Kogel, A .eds. Basic Clinical Radiobiology. 4th ed. London: 
Arnold, pp. 27–40 
 
85 
 
World Health Organisation. 2011. Ionising radiation [Online] 
Available at: http://www.who.int/ionizing_radiation/about/what_is_ir/en/  
(Accessed: April 2011) 
 
Yi, A., Kim, H-K. & Shin, H., et al. 2009. Radiation-induced complications after 
breast cancer radiation therapy: A pictorial review of multimodality imaging 
findings. Korean J Radiol, vol. 10, pp. 496-507. 
 
Zhou, B. & Elledge, S. 2000. The DNA damage response: putting checkpoints 
in perspective. Nature, vol. 408, pp. 433-439 
